Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
KRAS G12V-derived antigenic determinant refers to the tumor-specific neoantigen or peptide epitope generated by the somatic G12V mutation (glycine-to-valine substitution at codon 12) in the KRAS oncogene. KRAS is a small GTPase that plays a critical role in regulating cell growth, survival, and differentiation, and its G12V mutation is highly prevalent in aggressive malignancies such as pancreatic ductal adenocarcinoma, colorectal cancer, and non-small cell lung cancer. Because this mutation is unique to cancer cells and absent in healthy tissues, the resulting mutated peptide is processed and presented on the surface of tumor cells by human leukocyte antigen (HLA) molecules (most notably HLA-A*11:01 and HLA-A*03:01), serving as an ideal, highly specific target for cancer immunotherapy. Therapeutic strategies targeting the KRAS G12V-derived antigenic determinant include adoptive cell therapies like T-cell receptor-engineered T-cell (TCR-T) therapy (e.g., NW-301V, RE001), T-cell receptor-guided T-cell engagers (TCR-TCEs) or bispecific antibodies (e.g., MDG3010), and therapeutic cancer vaccines (e.g., ELI-002, mKRAS-VAX, and mRNA-based vaccines). These therapies aim to direct the patient's immune system to selectively recognize and destroy KRAS G12V-expressing tumor cells. Clinical development of these agents relies heavily on patient selection using biomarkers such as the presence of the KRAS G12V mutation and specific HLA genotypes. While these immunotherapies offer a promising, highly precise approach to treating difficult solid tumors, challenges include potential tumor immune escape via HLA downregulation, T-cell exhaustion, and the risk of systemic inflammatory responses like cytokine release syndrome.
Stimulation of host T-cell responses or redirection of engineered T-cells/T-cell engagers to specifically recognize and eliminate tumor cells presenting the KRAS G12V mutant peptide in complex with human leukocyte antigen (HLA) molecules.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on KRAS G12V-derived antigenic determinant (KRAS G12V neoantigen).